CA-MRSA is usually associated with young healthy individuals in the community, who have no risk factors for acquisition of HA-MRSA. Several reports have documented CA-MRSA infections affecting individuals in prisons, military personnel, athletic populations, male homosexuals and ethnic populations (native Alaskans and American Indians, Hawaiian islanders). CA-MRSA is primarily associated with skin and soft tissue infections (abscesses, cellulitis and furunculosis); however, there have been severe cases of CA-MRSA infection associated with septic shock, bacteraemia and necrotizing pneumonia. For a comprehensive review on CA-MRSA, see Zetola et al. 7 It remains unclear as to whether CA-MRSA evolved historically from the acquisition of SCCmec elements conferring methicillin resistance, through an altered penicillin-binding protein (PBP2 0 ) in the bacterial cell wall, within methicillin-susceptible S. aureus (MSSA) in the community or if CA-MRSA was originally derived from HA-MRSA.
More recently, infective endocarditis (IE) due to the involvement of CA-MRSA has been described. In order to identify cases of CA-MRSA IE, a thorough interrogation of the PubMed Search Engine was carried out by using several key words including 'endocarditis', 'MRSA' and 'community', seeking articles that were in print by July 2007 and which described clinical cases of IE associated with CA-MRSA. The determination of CA-MRSA was made by the original authors of the cases discussed, to include epidemiological, microbiological and molecular characteristics of each case, and a summary of these 23 published cases is detailed in Table 2 . To date, reports of CA-MRSA IE have been limited to highly industrialized and developed regions including North America, Europe, Asia and Australia, though the majority (68%) of cases have originated in the USA. As yet, there have been no reports from developing nations, although this may reflect reporting bias and/or the absence of high-quality microbiological characterization. From the known epidemiological information recorded, CA-MRSA IE has been primarily acquired within the community and associated with a young, healthy population with no known risk factors for the acquisition of IE. It should be noted, however, that a large proportion of cases have a documented history of some form of skin lesion, including furunculosis, cellulitis and/ or iv drug abuse. All cases reported to date have been associated with native valves, predominately the tricuspid valve (Table 3) .
Where there has been sufficient epidemiological information provided, a comparison of clinical characteristics and outcome 18 This comparison shows a close correlation of CA-MRSA IE to MSSA IE, particularly in terms of age, acquisition in the community, vegetation location and embolic complications. Mortality associated with CA-MRSA IE has been shown, to date from the limited numbers of cases reported, to be markedly lower at 13%, in comparison with either HA-MRSA IE or MSSA IE, which is 37.2% and 23.2%, respectively (Table 3) , whereas associated mortality due to Propionibacterium and Candida endocarditis has been 13.3% and 37%, respectively, as reported previously by ICE. 19, 20 Although CA-MRSA IE resembles MSSA IE more closely than MRSA IE, the antibiotic management of CA-MRSA IE requires a similar approach to treatment as MRSA IE, as a result of the resistance of CA-MRSA to b-lactam agents. Although CA-MRSA tends to be more susceptible to antibiotic agents than HA-MRSA, treatment should follow current international guidelines as described by the British Society for Antimicrobial Chemotherapy (BSAC), 21 the European Society for Cardiology (ESC) 22 and the American Heart Association (AHA) 23 ( Table 4) . In all the CA-MRSA IE cases described, patients received vancomycin, frequently combined with a second agent (rifampicin, gentamicin, linezolid, co-trimoxazole, daptomycin and clindamycin). In the majority of cases, the patients were treated solely by antimicrobial therapy; however, surgical intervention was performed in five cases, four of which had valve replacement and one case had a vegectomy. The mortality rate of 13% was markedly lower than that in MSSA IE or HA-MRSA IE (23% and 37%, respectively) ( Table 3) . As CA-MRSA is relatively more susceptible to treatment than HA-MRSA, this may eventually lead to a new set of specific treatment guidelines for CA-MRSA, as its antibiotic susceptibility may allow several novel combinations of agents to be used. However, it is difficult to evaluate such novel approaches, until clinical experience evolves. At present, we are not aware of any CA-MRSA that is resistant to vancomycin and, therefore, we do not believe that CA-MRSA should be regarded as being different in terms of the BSAC, AHA and ESC antibiotic guidelines. However, this is a situation that requires careful monitoring, as antibiotic susceptibility patterns may begin to evolve, if this organism becomes more endemic in healthcare settings, as is the case in the USA, with the associated diversity and quantity of anti-infectives used in the hospital setting. Given that CA-MRSA is an organism that resides on skin and outer epithelial surfaces, this location may play a significant Leading article 
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role in the potential introduction to the host. Consequently, it is important to give careful consideration to this ecological niche in relation to antibiotic prophylaxis. When the published cases are examined, none of the patients with CA-MRSA IE had documented classical risk factors for the acquisition of IE, e.g. heart murmur, structural heart disease or prior rheumatic fever. These data suggest that a new 'at risk' group may be emerging, namely, patients with some form of CA-MRSA skin lesion coupled with iv drug abuse or diabetes mellitus. At present, it is difficult to draw definitive conclusions, not least as the overall role of antibiotic prophylaxis for IE is currently undergoing major reappraisal. However, with increasing reports, careful consideration should be given to this potential new 'at risk' group. Cardiologists and microbiologists need to be aware of the growing significance of this organism and its potential to cause IE. CA-MRSA, although an organism with its origins in the community, has already emerged in nosocomial transmission within healthcare settings, particularly neonatal intensive care units, where it has been involved in several types of infections. Although a very rare event to date, the risk remains relating to the potential for nosocomial IE, from CA-MRSA acquired in the community, but spreading in the healthcare setting. Unlike conventional IE, CA-MRSA has a worrying trait, appearing to cause IE in otherwise healthy and young patients akin to its more common presentation with skin lesions. The combination of CA-MRSA in skin lesions and skin trauma through injection (iv drug abuse and diabetes mellitus) may represent a new susceptible into two doses for 6 weeks (infusion over at least 60 min) plus rifampicin 300 mg/24 h iv divided into three doses plus gentamicin 3 mg/kg/24 h iv (maximum of 240 mg/day) divided into three doses, all for 6-8 weeks vancomycin 30 mg/kg per 24 h iv in two equally divided doses for 6 weeks (adjust vancomycin dosage to achieve 1 h serum concentration of 30-45 mg/L and trough concentration of 10-15 mg/ L) plus rifampicin 900 mg per 24 h iv/ po in three equally divided doses for 6 weeks plus gentamicin 3 mg/kg per 24 h iv/im in two or three equally divided doses for 2 weeks. Paediatric dose: vancomycin 40 mg/kg per 24 h iv in two or three equally divided doses; rifampicin 20 mg/kg iv/po per 24 h in three equally divided doses up to adult dose; gentamicin 3 mg/kg per 24 h iv or im in three equally divided doses AHA, American Heart Association; BSAC, British Society for Antimicrobial Chemotherapy; ESC, European Society of Cardiology; iv, intravenously; im, intramuscularly; po, orally. a According to susceptibility.
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population for the acquisition of CA-MRSA IE. We therefore would encourage continued reporting and examination of the epidemiology of IE because of this causal organism in an attempt to define the optimal antibiotic treatment regimens, as well as the potential role (if any) for the prevention of this infection.
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